Enfortumab vedotin + Pembrolizumab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urothelial Carcinoma
Conditions
Urothelial Carcinoma
Trial Timeline
Jun 2, 2022 → Jun 1, 2027
NCT ID
NCT05239624About Enfortumab vedotin + Pembrolizumab
Enfortumab vedotin + Pembrolizumab is a phase 2 stage product being developed by Astellas Pharma for Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05239624. Target conditions include Urothelial Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07475806 | Phase 2 | Recruiting |
| NCT06906822 | Phase 2 | Recruiting |
| NCT06809140 | Phase 2 | Recruiting |
| NCT06470282 | Phase 1/2 | Recruiting |
| NCT05756569 | Phase 2 | Recruiting |
| NCT05239624 | Phase 2 | Recruiting |
| NCT04225117 | Phase 2 | Active |
Competing Products
20 competing products in Urothelial Carcinoma